Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

Targeting the epidermal growth factor receptor pathway in pancreatic cancer seems to be an attractive therapeutic approach. This study assessed the efficacy of cetuximab plus the combination of gemcitabine/oxaliplatin in metastatic pancreatic cancer. Eligible subjects had histological or cytological...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kullmann, F, Hollerbach, S, Dollinger, M M, Harder, J, Fuchs, M, Messmann, H, Trojan, J, Gäbele, E, Hinke, A, Hollerbach, C, Endlicher, E
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670003/
https://ncbi.nlm.nih.gov/pubmed/19293797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604983
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados